|
| Drug | Previous use | Tumor type/cell lines | Effect | Ref. |
|
| ATRA, RAR-α agonists | APL treatment; neuroblastoma treatment; skin disorders | BC/MCF-7; AML/HL60, THP-1; APL/NB4, NB4-R2; NB/HTLA-230; GBM/U251; OC/A2780 CSC | Decreases NRF2 binding to ARE sites; decreases NRF2 nuclear translocation | [347–350] |
| PHA-767491 | Cdc7/CDK9 inhibitor | PDAC/PANC-1, Capan-1; HCC/HepG2 | Decreases NRF2 nuclear translocation and activity | [351] |
| Sorafenib | Multi-Tyrosine kinase inhibitor; antiangiogenic therapy | CRC/DLD-1, HCT116; TC/FTC133, BC-PAP, 8505C; RC/ACHN, 786-O; CRC/DLD-1; HCC/HepG2, BEL7402-5FU, HuH-7; BC/MCF7, MDA-MB-231; NSCLC/CALU-3 | Decreases NRF2 expression and nuclear translocation | [352] |
| Auranofin | Rheumatoid arthritis | NSCLC/Calu-3, Calu-6, H522 | Decreases NRF2 activation | [353] |
| Clobetasol Propionate | Skin disorders | NSCLC/A549, H2228 | Decreases NRF2 nuclear accumulation and promotes β-TrCP-dependent NRF2 degradation | [354] |
| Camptothecin | Topoisomerase inhibitor; chemotherapy | HCC/HepG2, SMMC-7721; NSCLC/A549 | Decreases NRF2 expression | [23] |
| Valproic acid | Histone deacetylase inhibitor; epilepsy and seizure disorders; chemosensitizer | BC/MCF7; TC/BCPAP, TCP1, BHP10-3 | Decreases NRF2 nuclear content | [355] |
| Metformin | Antidiabetic drug | BC/MCF-7; CRC/HT-29; EC/RL95–2, Spec-2, Ishikawa; HCC/HepG2; NSCLC/A549; CC/HeLa | Decreases NRF2 mRNA and protein content; decreases NRF2 expression | [356–361] |
| Isoniazid | Antitubercular agent | HCC/HepG2 | Decreases NRF2 nuclear translocation | [362] |
|
